Gilead Sciences (GILD) Tops Q4 EPS by 1c; Authorizes $5B Buyback Plan; Receives 'Refuse to File' Notification from FDA
Tweet Send to a Friend
Get Alerts GILD Hot Sheet
Price: $55.74 -0.99%
Revenue Growth %: +11.0%
Financial Fact:
Interest expense: -81.79M
Today's EPS Names:
BORN, EFUT, ZOOM, More
Revenue Growth %: +11.0%
Financial Fact:
Interest expense: -81.79M
Today's EPS Names:
BORN, EFUT, ZOOM, More
Trade GILD Now!
Gilead Sciences Inc. (NASDAQ: GILD) reported Q4 EPS of $0.95, $0.01 better than the analyst estimate of $0.94. Revenue for the quarter came in at $2 billion versus the consensus estimate of $1.99 billion.
The company also announced that its Board has authorized an additional 3-year $5 billion buyback program.
In a separate press release, Gilead also announced that it received a "refuse to file" notification from the FDA on its NDA for single-tablet regimen of Truvada and TMC278.
UPDATE: Gilead shares are down about 2% in the after-hours session. The stock last traded at $37.44.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The company also announced that its Board has authorized an additional 3-year $5 billion buyback program.
In a separate press release, Gilead also announced that it received a "refuse to file" notification from the FDA on its NDA for single-tablet regimen of Truvada and TMC278.
UPDATE: Gilead shares are down about 2% in the after-hours session. The stock last traded at $37.44.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.C. Penney Co., Inc. (JCP) Posts Q1 Loss of $1.31/Share; Comps Down 16.6%
- TiVo, Inc. (TIVO) Tops Q1 EPS by 6c; Issues Solid Q2 Rev Outlook
- China New Borun Corp. (BORN) Posts Q1 EPS of RMB0.50
Create E-mail Alert Related Categories
Earnings, FDA, Hot Earnings, Stock Buybacks
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
